US 12,461,103 B2
Biomarker cereblon for diagnosing hepatocellular carcinoma, and novel monoclonal antibody specific thereto
Kyung Jin Lee, Hanam-si (KR); and Sin Hwang, Seoul (KR)
Assigned to UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, Ulsan (KR); and THE ASAN FOUNDATION, Seoul (KR)
Appl. No. 17/441,386
Filed by UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, Ulsan (KR); and THE ASAN FOUNDATION, Seoul (KR)
PCT Filed Mar. 23, 2020, PCT No. PCT/KR2020/003963
§ 371(c)(1), (2) Date Sep. 21, 2021,
PCT Pub. No. WO2020/197227, PCT Pub. Date Oct. 1, 2020.
Claims priority of application No. 10-2019-0032863 (KR), filed on Mar. 22, 2019.
Prior Publication US 2022/0178929 A1, Jun. 9, 2022
Int. Cl. G01N 33/574 (2006.01); C07K 16/18 (2006.01); C12N 5/16 (2006.01); C12Q 1/6886 (2018.01)
CPC G01N 33/57438 (2013.01) [C07K 16/18 (2013.01); C12N 5/163 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/471 (2013.01); G01N 2800/52 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A monoclonal antibody that specifically binds to cereblon (CRBN), produced by a hybridoma cell having accession number KCTC18596P or KCTC18598P.